Skip to main content

Table 2 Comparisons of parameters of lipid metabolism and liver and renal function between baseline and 3 months (N = 100)

From: Effect and safety of pemafibrate for patients with type 2 diabetes mellitus and hypertriglyceridemia: a retrospective analysis of clinical data

 

Baseline

3 months

p value

Triglycerides (mg/dL)

278.9

(136.4)

125.0

(48.0)

< 0.001

HDL-C (mg/dL)

49.2

(9.9)

56.2

(12.4)

< 0.001

Triglyceride/HDL-C ratio

5.99

(3.27)

2.43

(1.34)

< 0.001

LDL-C (mg/dL)

93.2

(19.9)

91.9

(23.3)

0.557

AST (IU/L)

28.0

(17.7)

24.5

(13.6)

< 0.001

ALT (IU/L)

35.2

(29.0)

23.9

(15.9)

< 0.001

ALP (IU/L)*

119.9

(85.2)

82.1

(59.4)

< 0.001

γGTP (IU/L)

64.8

(100.6)

36.5

(40.4)

< 0.001

Uric acid (mg/dL)

5.21

(1.22)

5.18

(1.22)

0.678

Serum creatinine (mg/dL)

0.78

(0.19)

0.78

(0.17)

0.196

eGFR (mL/min/1.73 m2)

77.5

(16.8)

75.3

(15.9)

0.037

  1. Data are mean (standard deviation) values. P values are for comparisons between baseline and 3 months after the start of pemafibrate
  2. HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; AST, aspartate aminotransferase; ALT, alanine transaminase; ALP, alkaline phosphate; γGTP, γ-glutamyl transpeptidase; eGFR, estimated glomerular filtration rate
  3. * The value of ALP measured by the JSCC method was converted to the value of the IFCC method